AMERICAN ACADEMY OF NEUROLOGY

Due to the COVID-19 pandemic, the 73rd AAN annual meeting was held in a fully virtual format from April 17-22.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

AMERICAN ACADEMY OF NEUROLOGY

Due to the COVID-19 pandemic, the AAN cancelled the 72nd annual meeting. This site enables you to access the presentations that were supposed to be presented if the AAN had happened.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

April 25-May 1 | Toronto, Canada

AMERICAN ACADEMY OF NEUROLOGY

April 17-22 | Virtual

AAN 2021 Virtual Annual Meeting

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study

Ashina M, et al; ePoster: P10.001

Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study

Tepper S, et al; ePoster: P10.032

Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the post marketing setting

Dodick D, et al; ePoster: P10.044

Design and population characteristics of patients treated with monoclonal antibody erenumab for assessment of long-term safety and tolerability and frequency of drug holidays in Germany (APOLLON)

Ortler S, et al; ePoster: P10.047

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO)

S. Tepper, R. B. Lipton, S. Silberstein, D. Kudrow, M. Ashina, U. Reuter, D. Dodick, F. Zhang, S. Cheng, D. D. Mikol
Poster number: P2.6-002

First-hand impressions of the monoclonal antibody erenumab from treated patients in Germany

C. Gaul, H. Israel-Willner, M. Koch, K. Schuh
Poster number: P3.6-001

First real-world evidence data for the monoclonal antibody erenumab from specialized migraine centers in Germany

A. Straube, P. Stude, K. Schuh, M. Koch
Poster number: P3.6-005

Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period

M. Ashina, P. J. Goadsby, U.Reuter, S. Silberstein,D.W.Dodick, D. E. Chou, J. Klatt, F. Xue, F. Zhang, S. Cheng, D. D. Mikol
Oral presentation: S8.001

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

A. Starling, S. Tepper, C. Bernstein, J. Ailani, F. Zhang, G. Paiva da Silva Lima, D. E. Chou
Oral presentation: S8.006

Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials

C. Lampl, J. Snellman, S. Ritter, J. Klatt
Poster number: P7.6-004

Changes in acute migraine-specific medications after initiating erenumab: Results from a real-world retrospective cohort study in the United States

SD. M. Hines, S. Shah, J. K. Multani,R. L. Wade, D. C. Buse, M. E. Bensink
Poster number: P11.6-001

Impact of an employer-provided migraine coaching program on burden and patient engagement: Results from interim analysis

L. Schaetz, T. Rimner, P. Pathak, J. Fang, D. Chandrasekhar, J. Mueller
Oral presentation: S47.004

Migraine polygenic risk score is associated with severity of migraine: Analysis of genotypic data from four placebo-controlled trials of erenumab

D.D. Mikol, H. Picard, J. Klatt, A. Wang, C. Peng, K. Stefansson
Oral presentation: S47.006

Economic burden increased with number of treatment failure in migraine patients: A retrospective claims database analysis in the united states

L. Newman, J. Huels, P. Vo, L. Zhou, C. Lopez Lopez, A. Cheadle, M. Olson, J. Fang
Oral presentation: S47.009

Cardiovascular safety of erenumab in patients with migraine and aura

M. Ashina, P. J Goadsby, D.W.Dodick, S. J Tepper, F. Xue, F. Zhang, J. Olearczyk, G. Paiva da Silva Lima
Oral presentation: S58.010



Click here for all published abstracts

click here

For more details please visit:

AAN 2020 Science Highlights

Click here for all published abstracts

click here
Erenumab is co-developed by Novartis and Amgen
MLR ID: 120740
Cookie Settings
© Copyright 2021 Novartis Pharma AG